Heparin inhaled - Ockham Biotech

Drug Profile

Heparin inhaled - Ockham Biotech

Alternative Names: Inhaled heparin - Ockham Biotech

Latest Information Update: 22 Apr 2016

Price : $50

At a glance

  • Originator Ockham Biotech
  • Class Anti-infectives; Anti-inflammatories; Antithrombotics; Bronchodilators; Heparins; Mucolytics
  • Mechanism of Action Deoxyribonuclease 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Asthma; Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2016 Efficacy and adverse event data from a phase II trial in Chronic obstructive pulmonary disease released by Ockham Biotech
  • 23 Feb 2016 Phase-II development is ongoing in Italy and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top